Christopher P. Guise
Auckland, AUK 1142, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.
Journal: ACS medicinal chemistry letters
Published: July 24, 2023
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 16, 2021
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 01, 2021
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
Journal: Molecular cancer therapeutics
Published: May 05, 2021
Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.
Journal: Cancer gene therapy
Published: September 18, 2020
Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy.
Journal: Biochemistry
Published: August 13, 2019
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
Journal: Bioorganic & medicinal chemistry letters
Published: December 09, 2018
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.
Journal: Clinical and translational radiation oncology
Published: December 07, 2018
2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Journal: European journal of medicinal chemistry
Published: March 06, 2017
2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.
Journal: ACS medicinal chemistry letters
Published: March 01, 2017
Last Updated: 09/26/2026